Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Mac S. Giballa who wrote (842)	10/4/1999 8:58:00 PM
From: JGoren	Read Replies (1) \| Respond to of 1906

NESP preliminary announcement was made last week. Amgen's NESP as Effective as Epogen, Abstract Says--reported Bloomberg on Sept. 27th, abstract summary of research to be presented in November. study of 522 patients on kidney dialysis found that those given NESP once a week, or once every two weeks, fared as well as those given Epogen 1-3 times a week. Same side effects, deaths and withdrawals in both groups. On Oct. 1, Bloomberg also reported osteoprotegerin, or OPG, in study of 52 postmenopausal women found signs that a single high-dose injection of OPG suppressed bone loss for at least 28 days. ''These results are encouraging. They confirm that the protein is actually active in humans,'' said Colin Dunstan, a scientist who is heading up development of OPG for Amgen.